- Previous Close
1.7000 - Open
1.6800 - Bid 1.6300 x 100
- Ask 1.7300 x 100
- Day's Range
1.3600 - 1.7500 - 52 Week Range
1.2600 - 3.1300 - Volume
110,221 - Avg. Volume
68,250 - Market Cap (intraday)
46.573M - Beta (5Y Monthly) 0.25
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7600 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.00
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
www.immixbio.comRecent News: IMMX
View MorePerformance Overview: IMMX
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IMMX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IMMX
View MoreValuation Measures
Market Cap
47.13M
Enterprise Value
30.52M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.56
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-66.11%
Return on Equity (ttm)
-147.33%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-21.61M
Diluted EPS (ttm)
-0.7600
Balance Sheet and Cash Flow
Total Cash (mrq)
17.68M
Total Debt/Equity (mrq)
8.11%
Levered Free Cash Flow (ttm)
-7.55M